Bloomington, Indiana – July 23, 2024 – Singota Solutions, a leading full-service CDMO (specializing in small batch aseptic filler, aseptic manufacturing solutions, cold chain pharmaceutical storage, gmp compliant warehouse facilities, and injectable formulation development) is pleased to announce the enhancement of its analytical capabilities with the addition of the Agilent 1290 Infinity II Bio-inert uHPLC system coupled with the XT Single Quad Mass Spectrometer. This advanced equipment will significantly bolster Singota’s formulation and analytical method development and transfer activities.
The addition of this state-of-the-art HPLC and mass spectrometry system allows Singota to offer more comprehensive support to its clients, particularly in the areas of stability studies and API purity assessments. Furthermore, the Agilent 1290 Infinity II Bio-inert uHPLC system enhances Singota’s ability to handle challenging method transfer projects. Its sophisticated software compensates for subtle differences across different HPLC systems, ensuring seamless transfer of methodologies from external laboratories.
This latest enhancement also strengthens Singota’s capacity to support clients facing rigorous regulatory requirements. With the ability to conduct in-depth impurity profiling, degradation studies, and high-precision quantitative analysis, Singota’s expanded analytical toolkit is designed to meet the increasing complexity of modern drug products. By investing in this advanced technology, Singota demonstrates a proactive approach to addressing the analytical challenges that often arise in early-phase development, allowing clients to anticipate regulatory demands and accelerate project timelines. This addition reflects Singota’s dedication to remaining a trusted partner in drug development, where precision, speed, and adaptability are paramount.
Singota Solutions remains committed to helping clients overcome obstacles at any phase of the drug development pipeline. By specializing in comprehensive services, Singota expedites the progression of products through development stages, advancing them toward clinical trials with unmatched speed and efficiency.
Read the full announcement with further details on this expansion, below:
For more information or project inquiries, please visit www.singota.com or connect with us on LinkedIn. You can also contact us via email at solutions@singota.com or by phone at 812-961-1770 (dial 4).